Table 1.
Characteristics of the included studies in this systematic review with meta-analysis.
| Study/Year | Sample Size | Study Design | Medical Condition | Mean/Range Age (Years) | Gender (F/M) | Intervention Drug | Control Group | Duration 1 | Primary Outcomes | Secondary Outcomes | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ross et al., 2016 [19] | 29 | Double-blind, randomized | Depression and anxiety associated with a life-threatening disease (cancer) | 56.28 | 18/11 | Psilocybin, 0.3 mg/kg | Niacin, 250 mg | (a) | 1 day post-dose 1 | BDI, STAI-State, STAI-Trait | - |
| (b) | 14 days post-dose 1 | ||||||||||
| (c) | 42 days post-dose 1 | ||||||||||
| (d) | 49 days post-dose 1 | ||||||||||
| (e) | 1 day post-dose 2 | ||||||||||
| (f) | 42 days post-dose 2 | ||||||||||
| (g) | 189 days post-dose 2 | ||||||||||
| Griffiths et al., 2016 [6] | 51 | Double-blind, randomized | Depression and anxiety associated with a life-threatening disease (cancer) | 56.3 | 25/26 | Psilocybin, 0.3 or 0.4 mg/kg | Psilocybin, 1 or 3 mg/70 kg | (a) | 28 days pre-crossover | BDI, STAI-Trait | SBP, DBP, HR |
| 35 days pre-crossover | |||||||||||
| (b) | 28 days pre-crossover | ||||||||||
| 35 days post-crossover | |||||||||||
| Grob et al., 2011 [20] | 12 | Pilot | Anxiety associated with a life-threatening disease (advanced-stage cancer) | From 36 to 58 | 11/1 | Psilocybin, 0.2 mg/kg | Niacin, 250 mg | (a) | 1 day | BDI, STAI-State, STAI-Trait | SBP, DBP, HR |
| (b) | 14 days | ||||||||||
1 The letters in unpaired parenthesis indicate the division of each study in several effect sizes.